【摘要】 Parthanatos是一种程序性细胞死亡方式，根据其分子机制也被称为多聚ADP核糖聚合酶1[poly(ADP-ribose)polymerase 1,PARP1]介导的凋亡诱导因子（apoptosis-inducing factor,AIF）和巨噬细胞迁移抑制因子（macrophage migration inhibitory factor,MIF）依赖的细胞死亡方式。Parthanatos是多种神经退行性疾病发病的主要原因，如帕金森症（Parkinson’s disease,PD）、阿尔莫茨海默症（Alzheimer’s disease,AD）、运动神经元病等，其还参与到部分肿瘤如肺癌、乳腺癌的发病过程中。因此，深入了解Parthanatos的分子机制对研究相关疾病的治疗策略至关重要。近年来有研究发现，通过调节Parthanatos中的关键蛋白PARP1、AIF、MIF进而有效调控Parthanatos的发生，有望成为多种疾病的治疗靶点。本文基于Parthanatos的具体分子机制，从抑制和促进Parthanatos层面对相关疾病治疗策略的研究进展作一综述。更多还原

【Abstract】 Parthanatos is a form of programmed cell death,which is also known as poly(ADP-ribose)polymerase 1(PARP1)-mediated apoptosis-inducing factor(AIF)and macrophage migration inhibitory factor(MIF)-dependent cell death according to its molecular mechanism. Parthanatos is the main cause of a variety of neurodegenerative diseases,such as Parkinson’s disease(PD),Alzheimer’s disease(AD),motor neuron disease,and is also involved in the pathogenesis of some tumors,such as lung cancer and breast cancer. Therefore,a thorough understanding of the molecular mechanism of Parthanatos is crucial for the therapeutic strategies of related diseases. In recent years,studies have found that effective regulation of the occurrence of Parthanatos by regulating the key proteins PARP1,AIF and MIF is expected to become a therapeutic target for many diseases. Based on the specific molecular mechanism of Parthanatos,this paper reviewed the research progress of therapeutic strategies for related diseases from the aspects of inhibiting and promoting Parthanatos.更多还原